About this Journal Submit a Manuscript Table of Contents
Advances in Urology
Volume 2013 (2013), Article ID 275945, 7 pages
http://dx.doi.org/10.1155/2013/275945
Review Article

Serum Testosterone Level, Testosterone Replacement Treatment, and Prostate Cancer

1Gazi University School of Medicine, Department of Urology, Besevler, 06125 Ankara, Turkey
2Ministry of Health, Ankara Numune Research and Training Hospital Third Department of Urology, Sihhiye, 06120 Ankara, Turkey
3Sisli Memorial Hospital, Department of Urology, 34120 Istanbul, Turkey

Received 19 June 2013; Accepted 20 August 2013

Academic Editor: Axel S. Merseburger

Copyright © 2013 Ali Atan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. He, M. Sengupta, V. A. Velkoff, K. A. DeBarros, and U. S. Census Bureau, Current Population Reports, U.S. Government Printing Office, Washington, DC, USA, 2005.
  2. C. G. Roehrborn, “Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations,” Review Urology, vol. 10, no. 1, pp. 14–25, 2008.
  3. G. Schreiber and M. Ziemer, “The aging male—diagnosis and therapy of late-onset hypogonadism,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 6, no. 4, pp. 273–279, 2008.
  4. A. Gray, H. A. Feldman, J. B. McKinlay, and C. Longcope, “Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study,” Journal of Clinical Endocrinology and Metabolism, vol. 73, no. 5, pp. 1016–1025, 1991. View at Scopus
  5. S. M. Harman, E. J. Metter, J. D. Tobin, J. Pearson, and M. R. Blackman, “Longitudinal effects of aging on serum total and free testosterone levels in healthy men,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 724–731, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. A. B. Araujo, G. R. Esche, V. Kupelian et al., “Prevalence of symptomatic androgen deficiency in men,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 11, pp. 4241–4247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. F. C. W. Wu, A. Tajar, S. R. Pye et al., “Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2737–2745, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Morgentaler, “Testosterone replacement therapy and prostate cancer,” Urologic Clinics of North America, vol. 34, no. 4, pp. 555–563, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Huggins and C. V. Hodges, “Studies on PCa I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate,” Cancer Research, vol. 1, no. 4, pp. 293–297, 1941.
  10. M. Khera, “Androgen replacement therapy after prostate cancer treatment,” Current Urology Reports, vol. 11, no. 6, pp. 393–399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Stattin, S. Lumme, L. Tenkanen et al., “High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study,” International Journal of Cancer, vol. 108, no. 3, pp. 418–424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Morgentaler, C. O. Bruning III, and W. C. DeWolf, “Occult prostate cancer in men with low serum testosterone levels,” Journal of the American Medical Association, vol. 276, no. 23, pp. 1904–1906, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Hoffman, W. C. DeWolf, and A. Morgentaler, “Is low serum free testosterone a marker for high grade prostate cancer?” Journal of Urology, vol. 163, no. 3, pp. 824–827, 2000. View at Scopus
  14. J. C. Massengill, L. Sun, J. W. Moul et al., “Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy,” Journal of Urology, vol. 169, no. 5, pp. 1670–1675, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ribeiro, P. Ruff, and G. Falkson, “Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer,” American Journal of Clinical Oncology, vol. 20, no. 6, pp. 605–608, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. S. S. Chen, K.-K. Chen, A. T. L. Lin, Y.-H. Chang, H. H. Wu, and L. S. Chang, “The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis,” BJU International, vol. 89, no. 7, pp. 710–713, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Yamamoto, J. Yonese, S. Kawakami et al., “Preoperative Serum Testosterone Level as an Independent Predictor of Treatment Failure following Radical Prostatectomy{A figure is presented},” European Urology, vol. 52, no. 3, pp. 696–701, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Mearini, E. Costantini, A. Zucchi et al., “Testosterone levels in benign prostatic hypertrophy and prostate cancer,” Urologia Internationalis, vol. 80, no. 2, pp. 134–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. P. J. Snyder, H. Peachey, J. A. Berlin et al., “Effects of testosterone replacement in hypogonadal men,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 8, pp. 2670–2677, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Wang, G. Cunningham, A. Dobs et al., “Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2085–2098, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. T. Guay and J. Jacobson, “The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction,” Journal of Sexual Medicine, vol. 4, no. 4, pp. 1046–1055, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Morales, A. M. Black, and L. E. Emerson, “Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations,” BJU International, vol. 103, no. 1, pp. 62–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Wang, E. Nieschlag, R. Swerdloff et al., “Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations,” European Urology, vol. 55, no. 1, pp. 121–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Ho, D. Damassa, P. W. Kwan, H. S. Seto, and I. Leav, “Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats,” Journal of Andrology, vol. 6, no. 5, pp. 279–290, 1985. View at Scopus
  25. A. M. Traish, D. F. Williams, N. D. Hoffman, and H. H. Wotiz, “Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates,” Progress in Clinical and Biological Research, vol. 262, pp. 145–160, 1988. View at Scopus
  26. L. S. Marks, N. A. Mazer, E. Mostaghel et al., “Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial,” Journal of the American Medical Association, vol. 296, no. 19, pp. 2351–2361, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. P. H. Gann, C. H. Hennekens, J. Ma, C. Longcope, and M. J. Stampfer, “Prospective study of sex hormone levels and risk of prostate cancer,” Journal of the National Cancer Institute, vol. 88, no. 16, pp. 1118–1126, 1996. View at Scopus
  28. J. K. Parsons, H. B. Carter, E. A. Platz, E. J. Wright, P. Landis, and E. J. Metter, “Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 9, pp. 2257–2260, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Morgentaler and E. L. Rhoden, “Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less,” Urology, vol. 68, no. 6, pp. 1263–1267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. I. M. Thompson, D. K. Pauler, P. J. Goodman et al., “Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter,” The New England Journal of Medicine, vol. 350, no. 22, pp. 2239–2321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. A. W. Roddam, N. E. Allen, P. Appleby, and T. J. Key, “Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies,” Journal of the National Cancer Institute, vol. 100, no. 3, pp. 170–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. K. R. Loughlin and J. P. Richie, “Prostate cancer after exogenous testosterone treatment for impotence,” Journal of Urology, vol. 157, no. 5, article 1845, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone, and D. J. Cosgrove, “Prostate cancer in men using testosterone supplementation,” Journal of Urology, vol. 174, no. 2, pp. 534–538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. L. J. G. Gooren, “A ten-year safety study of the oral androgen testosterone undecanoate,” Journal of Andrology, vol. 15, no. 3, pp. 212–215, 1994. View at Scopus
  35. C. S. Cooper, J. H. MacIndoe, P. J. Perry, W. R. Yates, and R. D. Williams, “The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men,” The Journal of Urology, vol. 156, no. 2, pp. 438–442, 1996. View at Scopus
  36. A. T. Guay, J. B. Perez, W. A. Fitaihi, and M. Vereb, “Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer,” Endocrine Practice, vol. 6, no. 2, pp. 132–138, 2000. View at Scopus
  37. R. E. Gerstenbluth, P. N. Maniam, E. W. Corty, and A. D. Seftel, “Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement,” Journal of Andrology, vol. 23, no. 6, pp. 922–926, 2002. View at Scopus
  38. E. L. Rhoden and A. Morgentaler, “Risks of testosterone-replacement therapy and recommendations for monitoring,” The New England Journal of Medicine, vol. 350, no. 5, pp. 482–492, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. O. M. Calof, A. B. Singh, M. L. Lee et al., “Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials,” Journals of Gerontology A, vol. 60, no. 11, pp. 1451–1457, 2005. View at Scopus
  40. D. McLaren, D. R. Siemens, J. Izard, A. Black, and A. Morales, “Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome,” BJU International, vol. 102, no. 9, pp. 1142–1146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Shabsigh, E. D. Crawford, A. Nehra, and K. M. Slawin, “Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review,” International Journal of Impotence Research, vol. 21, no. 1, pp. 9–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. M. R. Feneley and M. Carruthers, “Is testosterone treatment good for the prostate? Study of safety during long-term treatment,” The Journal of Sexual Medicine, vol. 9, no. 8, pp. 2138–2149, 2012.
  43. H. Isbarn, J. H. Pinthus, L. S. Marks et al., “Testosterone and prostate cancer: revisiting old paradigms,” European Urology, vol. 56, no. 1, pp. 48–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. E. L. Rhoden and A. Morgentaler, “Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia,” Journal of Urology, vol. 170, no. 6, pp. 2348–2351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. G. K. Lefkowitz, S. S. Taneja, J. Brown, J. Melamed, and H. Lepor, “Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels,” Journal of Urology, vol. 168, no. 4, pp. 1415–1418, 2002. View at Scopus
  46. A. Morgentaler, “Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer,” Journal of Sexual Medicine, vol. 6, no. 2, pp. 574–577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Morgentaler, L. I. Lipshultz, R. Bennett, M. Sweeney, D. Avila Jr., and M. Khera, “Testosterone therapy in men with untreated prostate cancer,” Journal of Urology, vol. 185, no. 4, pp. 1256–1260, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Morales, “Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry,” BJU International, vol. 107, no. 9, pp. 1369–1373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Bhasin, G. R. Cunningham, F. J. Hayes et al., “Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2536–2559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J. M. Kaufman and R. J. Graydon, “Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men,” Journal of Urology, vol. 172, no. 3, pp. 920–922, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. P. K. Agarwal and M. G. Oefelein, “Testosterone replacement therapy after primary treatment for prostate cancer,” Journal of Urology, vol. 173, no. 2, pp. 533–536, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Mulhall, L. Goldenberg, J. Narus, G. Gotto, R. Tal, and O. Nabulsi, “Outcomes of testosterone supplementation in hypogonadal men following radical prostatectomy,” The Journal of Urology, vol. 179, no. 4, pp. 426–427, 2008.
  53. M. Khera, E. D. Grober, B. Najari et al., “Testosterone replacement therapy following radical prostatectomy,” Journal of Sexual Medicine, vol. 6, no. 4, pp. 1165–1170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Isbarn, M. Fisch, H. Huland, M. Graefen, and F. Sommer, “Testosterone treatment after radical prostatectomy for pathologically organ-confined prostate cancer: results from a multiinstitutional study,” The Journal of Urology, vol. 183, no. 4, pp. 576–577, 2010.
  55. A. W. Pastuszak, A. M. Pearlman, W. S. Lai et al., “Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy,” The Journal of Urology, vol. 190, no. 2, pp. 639–644, 2013. View at Publisher · View at Google Scholar
  56. R. L. Leibowitz, T. B. Dorff, S. Tucker, J. Symanowski, and N. J. Vogelzang, “Testosterone replacement in prostate cancer survivors with hypogonadal symptoms,” BJU International, vol. 105, no. 10, pp. 1397–1401, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. M. F. Sarosdy, “Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy,” Cancer, vol. 109, no. 3, pp. 536–541, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. H. H. Davila, C. N. Arison, M. K. Hall, R. Salup, J. L. Lockhart, and R. E. Carrion, “Analysis of the PSA response after testosterone supplementation in patients who have previously received management for their localized prostate cancer,” The Journal of Urology, Supplement, vol. 179, 428, abstract 1247, 2008.
  59. A. W. Pastuszak, A. M. Pearlman, G. Godoy, B. J. Miles, L. I. Lipshultz, and M. Khera, “Testosterone replacement therapy in the setting of prostate cancer treated with radiation,” International Journal of Impotence Research, vol. 25, no. 1, pp. 24–28, 2013.
  60. G. Dohle, S. Arver, C. Bettocchi, et al., “Members of the EAU guidelines office. guidelines on male hypogonadism,” in Proceedings of the 27th EAU Annual Congress, EAU Guidelines, Paris, France, 2012.
  61. A. Morgentaler and A. M. Traish, “Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth,” European Urology, vol. 55, no. 2, pp. 310–321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. C. S. Cooper, P. J. Perry, A. E. T. Sparks, J. H. MacIndoe, W. R. Yates, and R. D. Williams, “Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men,” Journal of Urology, vol. 159, no. 2, pp. 441–443, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Bhasin, T. W. Storer, N. Berman et al., “The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men,” The New England Journal of Medicine, vol. 335, no. 1, pp. 1–7, 1996. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Ramsay and P. Schlegel, AUA Updates Series Vol 29, Lesson 32, 2010.
  65. K. L. Greene, P. C. Albertsen, R. J. Babaian et al., “Prostate specific antigen best practice statement: 2009 update,” Journal of Urology, vol. 182, no. 5, pp. 2232–2241, 2009. View at Publisher · View at Google Scholar · View at Scopus